A new drug to restore function following spinal cord injury.
Novoron Bioscience, Inc.
Novoron, a private biotechnology company, was founded in February 2013 to develop pharmaceutical therapies for nerve regeneration of the central nervous system (CNS). To date, we have received multiple Phase-1 grants from the National Institutes of Health (NIH) in order to pursue our passion: To further develop our ground-breaking discovery into therapies that promotes recovery for patients suffering from conditions related to a damaged CNS.
We are currently focused on developing a new drug to restore function for those suffering from spinal cord injury (SCI). Our proprietary scientific platform is the discovery that LRP1 protein is a receptor for molecular components of degraded myelin, which are a major obstacle to the ability of the CNS to regenerate. Blocking these interactions restores the growth capacity of CNS neurons.